The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

An international study reports that the combination of two drugs could significantly retard the development of a dangerous form of prostate cancer in men who have specific mutations in DNA repair ...

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

A new study introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients.

Niraparib is a “maintenance” drug approved to keep certain types of cancer from coming back, including ovarian cancer, ...

King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...

Boston (October 3, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, ...

Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company that operates its Healthcare business as EMD Serono in the US and Canada, today shared ...

MCLEAN, Va.--(BUSINESS WIRE)--Zephyr AI, a high-growth healthcare technology company committed to developing AI-Enabled Composite Biomarkers to expand the horizon of precision medicine in cancer drug ...